Condition
Type2 Diabetes Mellitus
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 114 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownA Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)NCT07654374 · 2026-07-17
RECRUITINGA Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes MellitusNCT07619157 · 2026-06-02
RECRUITINGSnapDandCGMinType2DMNCT07533604 · 2026-01-20
RECRUITINGEffect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLDNCT06449833 · 2024-06-01
RECRUITINGINcreasing the Uptake of DSMES Program and Addressing Social Needs in Low-Income VulneRablE ImmigrantsNCT07296211 · 2026-01-01
NOT_YET_RECRUITING"Effect of Omega-3 Supplementation as Add on Therapy on Glycemic Control and Lipid Profile in Type2 Diabetes Mellitus."NCT07352618 · 2026-01-01
ENROLLING_BY_INVITATIONDiet and Progression of CKD in Patients With Type 2 Diabetes MellitusNCT07169786 · 2025-10-01
NOT_YET_RECRUITINGComparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)NCT07203677 · 2025-09-19
COMPLETEDClinical Study to Assess the Safety, Efficacy and In-Use Tolerability of Herbal-Based Sugar Support Effervescent Tablets in Type-2 Diabetes Mellitus PatientsNCT06961019 · 2025-08-25
COMPLETEDA Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State StudyNCT07044765 · 2025-08-01
NOT_YET_RECRUITINGA Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy AdultsNCT07034781 · 2025-08-01
NOT_YET_RECRUITINGEffects of Marching Exercise With Cognitive Training on Physical, Cognitive Function, and Autonomic Cardiovascular Responses in Older Adults With Type 2 Diabetes MellitusNCT07330700 · 2025-07-10
COMPLETEDObservational Study on GER in Patients With Simple ObesityNCT07188571 · 2025-07-01
COMPLETEDA Study to Assess Effect of Glucocil® on Metabolic Health in Individuals With Prediabetes and Type 2 Diabetes Mellitus.NCT06496893 · 2024-09-12
COMPLETEDEffort During Resistance Training in Type 2 DiabetesNCT06497842 · 2024-09-10
COMPLETEDA Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminNCT06257966 · 2024-07-17
ACTIVE_NOT_RECRUITINGEffects of a Health Intervention on Fear of HypoglycemiaNCT06464900 · 2024-07-01
UNKNOWNA Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fed Conditions in Healthy Adult VolunteersNCT06289933 · 2024-03-05
COMPLETEDBioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting ConditionNCT06180109 · 2023-07-30
COMPLETEDNephroprotective Effect of Nicorandil in Type 2 Diabetes MellitusNCT06430125 · 2023-02-28
UNKNOWNPhase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes MellitusNCT05762471 · 2023-01-09
COMPLETEDAI Health Assistant and Type 2 DiabetesNCT05539066 · 2022-10-01
UNKNOWNWeb-based Diabetic Foot Care Training Prepared With the Health Belief Model for Type 2 Diabetes PatientsNCT05395442 · 2022-06-03
COMPLETEDThe Influencing Factors of 12 Week Efficacy of Polyethylene Glycol Losenatide in Type 2 Diabetes PatientsNCT05611684 · 2022-06-01
UNKNOWNEffects of Vitamin D Supplementation on SOD,IL-6 and Insulin Resistance in Type 2 Diabetes Mellitus (DM)NCT05596383 · 2022-02-12
UNKNOWNEfficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.NCT03766750 · 2021-12-01
WITHDRAWNHigh Protein Effect on Body Composition and Sarcopenia Markers in Older Patients With Type 2 Diabetes MellitusNCT05457088 · 2021-11-01
COMPLETEDEmpagliflozin Effect on Glucose ToxicityNCT03437330 · 2021-10-27
WITHDRAWNThe Effect of Multidomain Dietary Education in Type 2 Diabetic AdultsNCT05892861 · 2021-06-03
COMPLETEDA Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.NCT04810676 · 2021-04-16
COMPLETEDInvestigating Plasma Biomarker Molecules Associated With the Progression of Prediabetes to Overt Type 2 DiabetesNCT04851223 · 2021-03-22
UNKNOWNAnti-thrombotic and Glucose Lowering Therapy in Diabetic Patients Undergoing PCINCT04481997 · 2021-01-11
COMPLETEDFeasibility of an Online Exercise Community Among Individuals With Type 2 DiabetesNCT05668442 · 2020-11-21
COMPLETEDDiabetes Nutrition Education With Glycemic ControlNCT04440319 · 2020-07-01
COMPLETEDThe Metabolic Impact of Bariatric Surgery Compared to Best Diabetic Care on Manitoba's Urban Indigenous PopulationNCT03301545 · 2020-07-01
UNKNOWNChanges of Muramyl Dipeptide in Intestinal and Extra-intestinal DiseasesNCT04924686 · 2020-05-10
UNKNOWNResponse of Gut Microbiota in Type 2 Diabetes to Hypoglycemic AgentsNCT04287387 · 2020-03-02
UNKNOWNA Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396NCT04246190 · 2020-02-24
UNKNOWNA Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult VolunteersNCT04223895 · 2020-02-01
UNKNOWNA Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-375NCT04221360 · 2020-01-29
UNKNOWNMetabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes MellitusNCT03682445 · 2019-11-04
COMPLETEDScreening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular PreventionNCT04082091 · 2019-09-01
UNKNOWNClinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes MellitusNCT03973515 · 2019-08-27
COMPLETEDQatar Diabetes Mobile Application TrialNCT03998267 · 2019-08-22
UNKNOWNPharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1NCT04156685 · 2019-08-06
COMPLETEDPerformance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and PediatricsNCT03966911 · 2019-06-14
COMPLETEDGuide To Goals: A Novel Care Coordination Tool for Children With Type Two Diabetes (T2D)NCT03926598 · 2019-06-05
COMPLETEDTolerance & Responsiveness Improvement for Metformin (TRIM)NCT03670043 · 2019-03-19
COMPLETEDMil Familias Cohort Establishment: a Study to Understand Determinants of Diabetes and Its Complications Among US LatinosNCT03830840 · 2019-02-01
COMPLETEDSTAR Study Investigating Performance and Safety of the Medical Device SiPore15™NCT03823027 · 2019-01-28
COMPLETEDIRAPe, Irisin and IL-34 in Patients With Type 2 DiabetesNCT04107259 · 2019-01-19
COMPLETEDPharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 in Healthy AdultsNCT03849261 · 2019-01-14
UNKNOWNEffect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver DiseaseNCT03590626 · 2019-01-01
COMPLETEDExercise Volume and Beta-cell Function in T2D The DOSE-EX Randomized TrialNCT03769883 · 2018-12-12
COMPLETEDThe Progress of Diabetes Mellitus After HMS5552 Treatment in Type 2 Diabetes MellitusNCT04091854 · 2018-12-12
UNKNOWN"POWER2DM Evaluation Campaign"NCT03588104 · 2018-12-03
COMPLETEDFinancial Incentives for Low Socioeconomic Diabetic PatientsNCT03506230 · 2018-11-25
UNKNOWNDiabetes and Osteopathic Manipulative Medicine (OMM)NCT03663322 · 2018-11-15
UNKNOWNThe MHERO Study (Michigan's Hypertension, Diabetes, and Obesity Education Research Online)NCT03729479 · 2018-11-01
COMPLETEDSmectite Gel and Probiotic for Obesity and Insulin ResistanceNCT04293731 · 2018-11-01
COMPLETEDCommon interventions
placeboDRUG6BexagliflozinDRUG4PlaceboDIETARY_SUPPLEMENT4Comparator 1DRUG2Comparator 2DRUG2DulaglutideDRUG2EmpagliflozinDRUG2GlimepirideDRUG2LinagliptinDRUG2MetforminDRUG2PB-119 injectionBIOLOGICAL2PlaceboOTHER2SitagliptinDRUG2Test DrugDRUG20.8 proteinOTHER11.5 proteinOTHER125% reduction of basal insulin doseOTHER13:1 ratio Ketogenic dietOTHER1Acarbose TabletsDRUG1adzuki beanDIETARY_SUPPLEMENT1AI health assistantDEVICE1aleniglipronDRUG1alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranosideBEHAVIORAL1as usual careOTHER1Based on BCW Theory of Health EducationBEHAVIORAL1
Leading sponsors
Chong Kun Dang Pharmaceutical6Theracos5PegBio Co., Ltd.3AJU Pharm Co., Ltd.2Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics2Leiden University Medical Center2Mathias Ried-Larsen2Nanjing First Hospital, Nanjing Medical University2Peking Union Medical College Hospital2Sansum Diabetes Research Institute2Zhujiang Hospital2Aga Khan University1Andalas University1Assiut University1Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA1
Trial status mix
COMPLETED70
UNKNOWN28
WITHDRAWN5
NOT_YET_RECRUITING4
RECRUITING4
ACTIVE_NOT_RECRUITING2
ENROLLING_BY_INVITATION1
Phase mix
NA49
PHASE121
PHASE39
PHASE48
PHASE27
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.